Spotlight on E.coli in women’s genitourinary health

E. coli: the gut bacteria that wreaks havoc in your bladder and vagina

You have probably heard of E. coli (full name: Escherichia coli) in the context of food poisoning or Urinary Tract Infections (UTIs). 

E. coli are gram-negative, rod shaped bacteria that naturally live in the intestines of animals and humans.  Different strains of E.coli exist, ranging from beneficial or harmless to pathogenic and deadly.  In humans, for example, some E.coli strains in the gut actually help us produce vitamin K and can compete for space against more pathogenic bacteria.  However, some strains can be very harmful to us causing diarrhoea and invasive diseases.

Because of the proximity of the anus, vagina and urethra in women's anatomy, E. coli can migrate relatively easily from the anus into the vaginal canal, urethra and bladder.  Once there, it will fight for survival, and if it manages to replicate (many factors can influence this), it can cause disease.

Infections caused by E.coli in a woman’s genitourinary system.

E.coli can cause infections in the bladder, as UTIs, and in the vagina as Aerobic Vaginitis, and further up in the endometrium it may contribute to Pelvic Inflammatory Disease or poorer fertility outcomes such as pre-term birth.

UTIs caused by E.coli

E. coli is responsible for 75–95% of all urinary tract infections, making it by far the most common cause of bladder infection.

For many women, it can become a recurring nightmare. An estimated one in three women will experience at least one diagnosed UTI requiring prescription medication by the age of 24. Recurrent UTIs, defined as two or more episodes within six months, are reported in up to 25% of women within six months of an initial infection.

How E. coli gets into the bladder and why it's so hard to get rid of

What makes uropathogenic E. coli UPEC, the specific strain responsible for UTIs, so clinically troublesome is not just that it causes infection. Its how it does it.

UPEC is equipped with hair-like structures called pili, tiny protein appendages that extend from the bacteria’s surface.  At the tip of each pilus sits a protein, which acts like a molecular hook. 

• E. coli uses the naturally occurring mannose sugar on the bladder wall as a handle to grip onto, allowing it to cling tenaciously to the wall even as urine flows past.
• Once attached, UPEC can actually burrow into the bladder cells themselves. Research has shown that the bacteria can invade the bladder wall and replicate intracellularly, hiding inside cells, sheltered from antibiotics and the immune response.

This is one reason why UTIs can appear to clear up and then return within weeks: the infection was never fully eradicated.

Think of UPEC as an expert squatter. It finds the door handle (mannose), lets itself in, locks the door from the inside (intracellular invasion), and waits.  Antibiotics can clear what is visible, but not always what is hiding.

The link between your vaginal microbiome and recurrent UTIs

Women with low Lactobacillus levels are significantly more likely to carry E. coli in the vaginal microbiome, and research shows the vagina can act as a persistent reservoir between infections. Crucially, E. coli doesn't merely rest on vaginal cells: it can invade them (as it does in the bladder), allowing the bacteria to survive even after a UTI has apparently cleared.

These vaginal reservoirs can then seed the urinary tract, triggering new or recurring infections, which is why so many women experience a relapse weeks or months after a course of antibiotics has seemingly resolved the problem.

Why Lactobacillus is your first line of defence

A healthy vaginal microbiome is a dense, well-established ecosystem, and when Lactobacillus dominates, there is simply little room for E. coli to gain foothold. Lactobacilli produces lactic acid and hydrogen peroxide that keeps vaginal pH below 4.5, an environment where E. coli, which prefers alkaline conditions, struggles to establish itself.  When Lactobacillus levels fall through antibiotic use, hormonal changes, or stress, pH rises, the barrier weakens, and opportunistic bacteria like E. coli seize the space left behind.

This dynamic explains why recurrent UTIs can follow antibiotic treatment. Despite appropriate therapy, 20–30% of women with an initial UTI will develop a recurrent infection within 4–6 months.  Antibiotics clear the infection but simultaneously deplete the protective Lactobacillus population, removing the very defence system that was preventing reinfection in the first place. It is a cycle that leaves many women feeling like there is no way out.

Where D-mannose comes in

D-mannose is a naturally occurring sugar that passes through the digestive system largely unmetabolised and is excreted into the urine, where it travels through the urinary tract and into the bladder. Once there, it works through a mechanism called competitive inhibition. E. coli uses tiny hooks to grip onto receptors on the bladder wall,  but D-mannose is structurally so similar to those receptors that the bacteria attach to it instead. 

The E. coli is essentially tricked into grabbing the wrong target and is swept out of the body with the next urination, before it ever gets the chance to establish an infection.

A two-pronged approach to breaking the cycle

The science points to a dual strategy for women who struggle with recurrent UTIs: restore the microbiome, and disrupt E. coli adhesion (via D mannose). A Lactobacillus-dominant environment remains the most powerful natural defence against E. coli colonisation, particularly strains like Lactobacillus crispatus, jensenii, rhamnosus and gasseri, which support both vaginal and urinary tract microbiome health and reduce pathogen adhesion over time.

Our Ultimate UT probiotic is formulated around exactly this approach

Combining D-mannose to block E. coli from binding to the bladder lining, with clinically studied Lactobacillus strains native to a healthy vaginal microbiome that can actively outcompete E. coli for space.

Designed for women who are tired of the antibiotic cycle and want a microbiome-informed, evidence-based alternative. View Ultimate UT. 

References / further reading

Esposito G & Cipriani S (2022). Systematic review of the effect of D-mannose with or without other drugs in the treatment of symptoms of UTI/cystitis. Biomedical Reports. doi: 10.3892/br.2022.1552

Hayward G et al. (2024). D-mannose for prevention of recurrent urinary tract infection among women: a randomised clinical trial. JAMA Internal Medicine. doi: 10.1001/jamainternmed.2024.0264

Wagenlehner F et al. (2022). Why D-mannose may be as efficient as antibiotics in the treatment of acute uncomplicated lower UTIs. Frontiers in Medicine. doi: 10.3389/fmed.2022.796709

Zhou Y et al. (2023). Urinary tract infections caused by uropathogenic Escherichia coli: mechanisms of infection and treatment options. International Journal of Molecular Sciences. doi: 10.3390/ijms241310537

Chen R et al. (2024). Incidence and recurrence of urinary tract infections caused by uropathogenic Escherichia coli: a retrospective cohort study. Research and Reports in Urology. doi: 10.2147/RRU.S470605

Jaure A & Wong G (2022). D-Mannose for preventing and treating urinary tract infections. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.CD013608

This article is for educational purposes and does not constitute medical advice. If you are experiencing recurrent UTIs, please speak to your GP or a qualified clinician